NEW YORK, Oct. 2, 2020 /PRNewswire/ -- New Ventures Funds
has launched a new corporate brand identity and changed its name to
Scientia Ventures. The new website for the firm can be found at:
www.scientiavc.com. This reflects the broadening of the firm's
strategic direction since launching its 3rd fund in 2017
to reflect its focus on transformational science and technology in
healthcare. The announcement follows two recent successful IPO's of
portfolio companies: ADC Therapeutics (NYSE: ADCT) and Royalty
Pharma (NASDAQ: RPRX); and successful Phase 3 clinical trials for
two of its portfolio companies: FibroGen (NASDAQ: FGEN) and
Intra-Cellular Therapies (NASDAQ: ITCI).
Harry Glorikian, Partner, who
leads the firm's work in digital systems explained: "We track and
invest in the evolution of life sciences and healthcare systems. We
are empowered by a combination of advances in the areas of
information technology and biological data as applied to
diagnostics and therapeutics. This is where we see the biggest
impact for our investors and for the medical field. The name
Scientia Ventures highlights our investment at what we believe is a
major inflection point in these areas: the opportunity for
industrialization of the technology and building successful
companies." Harry Glorikian added:
"If the difference between evolution and revolution is the speed of
change, then healthcare now is in the mode of revolutionary change.
This is creating unique opportunities in healthcare and the life
sciences."
"We are encouraged by the tremendous mindset shift that is going
on as Big Pharma, biotech and healthcare startups all look at
themselves not as biotech or healthcare but as data science
companies. It is an exciting time for venture capital to make a
difference," said Rory Riggs, a
Founding Partner.
"We believe this shift has the potential to revolutionize the
drug development process, by reducing uncertainty, while generating
unique intellectual property and allowing companies to bring
breakthrough therapies to market more rapidly. Importantly, these
therapies help patients get effective care and simultaneously drive
down industry-wide costs," said Richard
Warburg, Partner and leader of the firm's work
on drug development.
Commenting on the announcement, Jonathan
Finn, CFA, a Founding Partner said, "This name change shows
the strategic evolution of our firm. We continue to invest in
transformative healthcare concepts and business models. Our
strategy has evolved to parallel the change in technology."
About Scientia Ventures
Scientia Ventures invests in
early to mid-stage technology companies that target computational
biology and chemistry, the digitization of medicine, and digital
therapies as well as traditional drug development companies at the
cutting edge of the life sciences. Our strength is working with
entrepreneurs and big ideas to build companies with the potential
to transform healthcare. Our Partners, many of whom are former
founders, operators, or CEO's of important healthcare companies,
have a long history of working together and have domain expertise
across healthcare, finance, and intellectual property.
Contact:
|
|
Scientia
Ventures
|
William
Martin
|
One Liberty
Plaza
|
Investor
Relations
|
46th
Floor
|
w.martin@scientiavc.com
|
New York, NY
10006
|
|
This is not an offer to purchase or sell, nor a solicitation of
an offer to purchase or sell an interest in The Fund or any other
financial instrument. Any offering or solicitation will be made
only to qualified prospective investors pursuant to the offering
memorandum, and the subscription documents, all of which should be
read in their entirety.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/new-ventures-funds-rebrands-as-scientia-ventures-301144560.html
SOURCE Scientia Ventures